<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03989570</url>
  </required_header>
  <id_info>
    <org_study_id>73-7/2018</org_study_id>
    <nct_id>NCT03989570</nct_id>
  </id_info>
  <brief_title>Transversus Abdominis Plane Block Versus Erector Spinae Plane Block</brief_title>
  <official_title>Ultrasound Guided Transversus Abdominis Plane Block Versus Erector Spinae Plane Block in Patients Undergoing Emergency Laparotomies.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hassan Mokhtar Elshorbagy Hetta</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Minia University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The TAP block, first described by Rafi in 2001, is comprised of deposition of a local
      anesthetic into the anatomical plane between the internal oblique and transverses abdominis
      muscles, where thess thoracoabdominal nerves (T6-L1) contribute to the main sensory supply of
      the skin, muscles, and parietal peritoneum of the anterior abdominal wall. These nerves
      branch and communicate extensively with each other in the TAP .

      Erector spinae plane (ESP) block is a recently described interfascial block in which the
      local anaesthectic is placed over or below the plane of the erector spinae muscle, near where
      the spinal nerves come out from the spine before they start to divide. Some publications have
      shown its effectiveness in treating thoracic and abdominal postoperative pain.

      Postoperative pain is the major obstacle for early postoperative ambulation and increases the
      risk of venous thromboembolism, respiratory complications and prolongs the hospital stay.
      Parietal pain is the chief component of postoperative pain after abdominal surgeries. Large
      doses of opioids are required to mitigate this pain, but they are poorly tolerated.
      Multimodal analgesia is effective in handling postoperative pain and in attenuating the side
      effects of large doses of a single analgesic .
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Group I (A group): Will undergo ESP block with 40 ml bupivacine 0.25% (20 ml on each side),
      and TAP block with 40 ml saline 0.9% (20 ml on each side).

      Group II (B group): Will undergo TAP block with 40 ml bupivacine 0.25% (20 ml on each side),
      and ESP block with 40 ml saline 0.9% (20 ml on each side).

      Group III (C group): anesthetized with the protocol followed by Minia University Hospital The
      medication will be prepared and supplied in similar syringes by an anesthetist not included
      in the management of the patint or data collection.

      Methods:

      Following placement of the standard monitors, intravenous access will secured and the
      patients will started on IV fluids. Anesthesia will be induced with 0.04 mg/kg midazolam, 2
      μg/kg fentanyl, and titrated doses of propofol. Endotracheal intubation will facilitated with
      0.5 mg/kg of atracurium. Isoflurane 1.2%, will be used for anesthetic maintenance After
      induction of anesthesia, stabilizing the patient's hemodynamics, and before surgical
      incision, ESB &amp; TAP block will be performed. With the patient in the supine position, the
      site of the ultrasound and needle entry will be sterilized. The TAP block will be performed
      laterally behind the midaxillary line between the iliac crest and the most inferior extent of
      the ribs. The plane between the internal oblique and transversus abdominis muscle will be
      located around the midaxillary line with the probe transverse to the abdomen. Anteriorly,The
      needle will be passed to come in plane with the ultrasound beam and placed between
      transversus and internal oblique posterior to the midaxillary line then, the local anesthetic
      will be injected. Then the patient will turn in lateral position, the site of the ultrasound
      and needle entry will be sterilized. The ESP block will be performed into a fascial plane
      between the deep surface of erector spinae muscle and the transverse processes
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 15, 2019</start_date>
  <completion_date type="Actual">February 12, 2020</completion_date>
  <primary_completion_date type="Actual">February 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time of First Post Operative Analgesic Request</measure>
    <time_frame>24 hours</time_frame>
    <description>the pain will be assisted based on the time for the first dose of rescue analgesia</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Postoperative Total Fentanyl Requirement</measure>
    <time_frame>24 hours</time_frame>
    <description>The total amount of postoperative fentanyl in milligram was given to the patient as rescue analgesia during 24 hours</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Any Adverse Events</measure>
    <time_frame>5 days</time_frame>
    <description>adverse events related to technique or drugs</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Postoperative Pain</condition>
  <condition>Laparotomy</condition>
  <arm_group>
    <arm_group_label>Group I (A group)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>31 patients Will undergo ESP block with 40 ml bupivacine 0.25% (20 ml on each side), and TAP block with 40 ml saline 0.9% (20 ml on each side).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group II (B group)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>31patients Will undergo TAP block with 40 ml bupivacine 0.25% (20 ml on each side), and ESP block with 40 ml saline 0.9% (20 ml on each side).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group III (C group)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>31 patients anesthetized with the protocol followed by Minia University Hospital</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>transversus abdominis plane block</intervention_name>
    <description>The TAP block will be performed laterally behind the midaxillary line between the iliac crest and the most inferior extent of the ribs. The plane between the internal oblique and transversus abdominis muscle will be located around the midaxillary line with the probe transverse to the abdomen. Anteriorly,The needle will be passed to come in plane with the ultrasound beam and placed between transversus and internal oblique posterior to the midaxillary line then, the local anesthetic will be injected</description>
    <arm_group_label>Group II (B group)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>erector spinae plane block</intervention_name>
    <description>The ESP block will be performed into a fascial plane between the deep surface of erector spinae muscle and the transverse processes</description>
    <arm_group_label>Group I (A group)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>control group</intervention_name>
    <description>placebo</description>
    <arm_group_label>Group III (C group)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1. Age18-70 . 2. Both gender . 3 .Emergency laparotomies . 4. ASA I-III .

        Exclusion Criteria:

          1. Drug allergy .

          2. Morbid obesity (BMI &gt;40 kg/m2) .

          3. Psychiatric disorder .

          4. Opioid dependence .

          5. patient refuse
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nagy S. Ali, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Minia University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Abeer A Hassanien</last_name>
    <role>Study Director</role>
    <affiliation>Minia University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Minia University Hospital</name>
      <address>
        <city>Minya</city>
        <zip>61511</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>May 4, 2019</study_first_submitted>
  <study_first_submitted_qc>June 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 18, 2019</study_first_posted>
  <results_first_submitted>February 11, 2020</results_first_submitted>
  <results_first_submitted_qc>March 24, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">March 25, 2020</results_first_posted>
  <last_update_submitted>June 18, 2020</last_update_submitted>
  <last_update_submitted_qc>June 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Minia University</investigator_affiliation>
    <investigator_full_name>Hassan Mokhtar Elshorbagy Hetta</investigator_full_name>
    <investigator_title>assistant lecture</investigator_title>
  </responsible_party>
  <keyword>Erector Spinae Plane Block</keyword>
  <keyword>Transversus Abdominis Plane Block</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 8, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/70/NCT03989570/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>7 patient refuse to participate</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Group I (A Group)</title>
          <description>31 patients Will undergo ESP block with 40 ml bupivacine 0.25% (20 ml on each side), and TAP block with 40 ml saline 0.9% (20 ml on each side).
erector spinae plane block: The ESP block will be performed into a fascial plane between the deep surface of erector spinae muscle and the transverse processes</description>
        </group>
        <group group_id="P2">
          <title>Group II (B Group)</title>
          <description>31patients Will undergo TAP block with 40 ml bupivacine 0.25% (20 ml on each side), and ESP block with 40 ml saline 0.9% (20 ml on each side).
transversus abdominis plane block: The TAP block will be performed laterally behind the midaxillary line between the iliac crest and the most inferior extent of the ribs. The plane between the internal oblique and transversus abdominis muscle will be located around the midaxillary line with the probe transverse to the abdomen. Anteriorly,The needle will be passed to come in plane with the ultrasound beam and placed between transversus and internal oblique posterior to the midaxillary line then, the local anesthetic will be injected</description>
        </group>
        <group group_id="P3">
          <title>Group III (C Group)</title>
          <description>31 patients anesthetized with the protocol followed by Minia University Hospital
control group: placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="31"/>
                <participants group_id="P3" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="31"/>
                <participants group_id="P3" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group I (A Group)</title>
          <description>31 patients Will undergo ESP block with 40 ml bupivacine 0.25% (20 ml on each side), and TAP block with 40 ml saline 0.9% (20 ml on each side).
erector spinae plane block: The ESP block will be performed into a fascial plane between the deep surface of erector spinae muscle and the transverse processes</description>
        </group>
        <group group_id="B2">
          <title>Group II (B Group)</title>
          <description>31patients Will undergo TAP block with 40 ml bupivacine 0.25% (20 ml on each side), and ESP block with 40 ml saline 0.9% (20 ml on each side).
transversus abdominis plane block: The TAP block will be performed laterally behind the midaxillary line between the iliac crest and the most inferior extent of the ribs. The plane between the internal oblique and transversus abdominis muscle will be located around the midaxillary line with the probe transverse to the abdomen. Anteriorly,The needle will be passed to come in plane with the ultrasound beam and placed between transversus and internal oblique posterior to the midaxillary line then, the local anesthetic will be injected</description>
        </group>
        <group group_id="B3">
          <title>Group III (C Group)</title>
          <description>31 patients anesthetized with the protocol followed by Minia University Hospital
control group: placebo</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="31"/>
            <count group_id="B2" value="31"/>
            <count group_id="B3" value="31"/>
            <count group_id="B4" value="93"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45.8" spread="14.9"/>
                    <measurement group_id="B2" value="47.4" spread="11.8"/>
                    <measurement group_id="B3" value="43.6" spread="13.7"/>
                    <measurement group_id="B4" value="45.61" spread="13.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="45"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="31"/>
                    <measurement group_id="B4" value="93"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="31"/>
                    <measurement group_id="B4" value="93"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Egypt</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="31"/>
                    <measurement group_id="B4" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time of First Post Operative Analgesic Request</title>
        <description>the pain will be assisted based on the time for the first dose of rescue analgesia</description>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group I (A Group)</title>
            <description>31 patients Will undergo ESP block with 40 ml bupivacine 0.25% (20 ml on each side), and TAP block with 40 ml saline 0.9% (20 ml on each side).
erector spinae plane block: The ESP block will be performed into a fascial plane between the deep surface of erector spinae muscle and the transverse processes</description>
          </group>
          <group group_id="O2">
            <title>Group II (B Group)</title>
            <description>31patients Will undergo TAP block with 40 ml bupivacine 0.25% (20 ml on each side), and ESP block with 40 ml saline 0.9% (20 ml on each side).
transversus abdominis plane block: The TAP block will be performed laterally behind the midaxillary line between the iliac crest and the most inferior extent of the ribs. The plane between the internal oblique and transversus abdominis muscle will be located around the midaxillary line with the probe transverse to the abdomen. Anteriorly,The needle will be passed to come in plane with the ultrasound beam and placed between transversus and internal oblique posterior to the midaxillary line then, the local anesthetic will be injected</description>
          </group>
          <group group_id="O3">
            <title>Group III (C Group)</title>
            <description>31 patients anesthetized with the protocol followed by Minia University Hospital
control group: placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Time of First Post Operative Analgesic Request</title>
          <description>the pain will be assisted based on the time for the first dose of rescue analgesia</description>
          <units>Hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.9" spread="5.7"/>
                    <measurement group_id="O2" value="6.5" spread="2.2"/>
                    <measurement group_id="O3" value="2.8" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Postoperative Total Fentanyl Requirement</title>
        <description>The total amount of postoperative fentanyl in milligram was given to the patient as rescue analgesia during 24 hours</description>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group I (A Group)</title>
            <description>31 patients Will undergo ESP block with 40 ml bupivacine 0.25% (20 ml on each side), and TAP block with 40 ml saline 0.9% (20 ml on each side).
erector spinae plane block: The ESP block will be performed into a fascial plane between the deep surface of erector spinae muscle and the transverse processes</description>
          </group>
          <group group_id="O2">
            <title>Group II (B Group)</title>
            <description>31patients Will undergo TAP block with 40 ml bupivacine 0.25% (20 ml on each side), and ESP block with 40 ml saline 0.9% (20 ml on each side).
transversus abdominis plane block: The TAP block will be performed laterally behind the midaxillary line between the iliac crest and the most inferior extent of the ribs. The plane between the internal oblique and transversus abdominis muscle will be located around the midaxillary line with the probe transverse to the abdomen. Anteriorly,The needle will be passed to come in plane with the ultrasound beam and placed between transversus and internal oblique posterior to the midaxillary line then, the local anesthetic will be injected</description>
          </group>
          <group group_id="O3">
            <title>Group III (C Group)</title>
            <description>31 patients anesthetized with the protocol followed by Minia University Hospital
control group: placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Postoperative Total Fentanyl Requirement</title>
          <description>The total amount of postoperative fentanyl in milligram was given to the patient as rescue analgesia during 24 hours</description>
          <units>Milligram</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.3" spread="26.7"/>
                    <measurement group_id="O2" value="111" spread="38.1"/>
                    <measurement group_id="O3" value="175" spread="38.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Any Adverse Events</title>
        <description>adverse events related to technique or drugs</description>
        <time_frame>5 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group I (A Group)</title>
            <description>31 patients Will undergo ESP block with 40 ml bupivacine 0.25% (20 ml on each side), and TAP block with 40 ml saline 0.9% (20 ml on each side).
erector spinae plane block: The ESP block will be performed into a fascial plane between the deep surface of erector spinae muscle and the transverse processes</description>
          </group>
          <group group_id="O2">
            <title>Group II (B Group)</title>
            <description>31patients Will undergo TAP block with 40 ml bupivacine 0.25% (20 ml on each side), and ESP block with 40 ml saline 0.9% (20 ml on each side).
transversus abdominis plane block: The TAP block will be performed laterally behind the midaxillary line between the iliac crest and the most inferior extent of the ribs. The plane between the internal oblique and transversus abdominis muscle will be located around the midaxillary line with the probe transverse to the abdomen. Anteriorly,The needle will be passed to come in plane with the ultrasound beam and placed between transversus and internal oblique posterior to the midaxillary line then, the local anesthetic will be injected</description>
          </group>
          <group group_id="O3">
            <title>Group III (C Group)</title>
            <description>31 patients anesthetized with the protocol followed by Minia University Hospital
control group: placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Any Adverse Events</title>
          <description>adverse events related to technique or drugs</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>5 days</time_frame>
      <desc>All patients were under control and receive the best care of management Our techniques don’t make any side effects or affect patients outcome</desc>
      <group_list>
        <group group_id="E1">
          <title>Group I (A Group)</title>
          <description>31 patients Will undergo ESP block with 40 ml bupivacine 0.25% (20 ml on each side), and TAP block with 40 ml saline 0.9% (20 ml on each side).
erector spinae plane block: The ESP block will be performed into a fascial plane between the deep surface of erector spinae muscle and the transverse processes</description>
        </group>
        <group group_id="E2">
          <title>Group II (B Group)</title>
          <description>31patients Will undergo TAP block with 40 ml bupivacine 0.25% (20 ml on each side), and ESP block with 40 ml saline 0.9% (20 ml on each side).
transversus abdominis plane block: The TAP block will be performed laterally behind the midaxillary line between the iliac crest and the most inferior extent of the ribs. The plane between the internal oblique and transversus abdominis muscle will be located around the midaxillary line with the probe transverse to the abdomen. Anteriorly,The needle will be passed to come in plane with the ultrasound beam and placed between transversus and internal oblique posterior to the midaxillary line then, the local anesthetic will be injected</description>
        </group>
        <group group_id="E3">
          <title>Group III (C Group)</title>
          <description>31 patients anesthetized with the protocol followed by Minia University Hospital
control group: placebo</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Hassan Elshorbagy</name_or_title>
      <organization>Minia university</organization>
      <phone>1204427271 ext 0020</phone>
      <email>Hassan.Hetta@mu.edu.eg</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

